A novel immunological model for the study of prostate cancer

Navesh Sharma, Jun Luo, Dawn A. Kirschmann, Yunxia O'Malley, Michael E.C. Robbins, Emmanuel T. Akporiaye, David M. Lubaroff, Paul M. Heidger, Mary J.C. Hendrix

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The Dunning R-3327 rat prostatic adenocarcinoma is a widely accepted model for in vivo experimental studies of prostate cancer. We have previously derived phenotypically distinct cell lines from a s.c. tumor resulting from the inoculation of the R-3327-5 subclone into Copenhagen rats. In this study, we report studies using a gelatin sponge model for the delivery of tumor cells and the retrieval of tumor-specific leukocytes responsive to different prostatic cell lines. S.c. preimplanted sponges were inoculated with tumor cells previously selected for differential properties of tumor formation and metastasis and examined for leukocyte content at time points of 1, 3, and 5 weeks after tumor cell inoculation. Cytospin and flow cytometric analyses revealed fewer tumor-associated leukocytes present in sponges inoculated with tumorigenic R-3327-5' and R-3327-5'B lines, with lesser sponge degradation, than in experiments with the nontumorigenic R-3327-5'A line, suggestive of a tumor cell-induced immunomodulatory mechanism. Morphological studies indicate an intermittent tumor growth pattern that gradually disappears in sponges inoculated with the nontumorigenic R-3327-5'A cells but a robust growth pattern in sponges inoculated with the tumorigenic cell lines. Cytokine analyses show the secretion of higher levels of active transforming growth factor-β by the more invasive and metastatic lines. Total transforming growth factor-β levels are higher in the epithelial, tumorigenic R-3327-5'B line. Additionally, the more tumorigenic lines secrete interleukin 10, a potent immunosuppressive molecule. In this report, we demonstrate the ability to retrieve viable leukocyte populations from a prostate tumor line bearing sponges, which offers an important model for further in vitro and in vivo manipulations and holds promise for testing adoptive immunotherapeutic strategies.

Original languageEnglish (US)
Pages (from-to)2271-2276
Number of pages6
JournalCancer Research
Volume59
Issue number10
StatePublished - May 15 1999

Fingerprint

Immunological Models
Prostatic Neoplasms
Porifera
Neoplasms
Leukocytes
Transforming Growth Factors
Cell Line
Gelatin
Immunosuppressive Agents
Growth
Interleukin-10
Prostate
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sharma, N., Luo, J., Kirschmann, D. A., O'Malley, Y., Robbins, M. E. C., Akporiaye, E. T., ... Hendrix, M. J. C. (1999). A novel immunological model for the study of prostate cancer. Cancer Research, 59(10), 2271-2276.
Sharma, Navesh ; Luo, Jun ; Kirschmann, Dawn A. ; O'Malley, Yunxia ; Robbins, Michael E.C. ; Akporiaye, Emmanuel T. ; Lubaroff, David M. ; Heidger, Paul M. ; Hendrix, Mary J.C. / A novel immunological model for the study of prostate cancer. In: Cancer Research. 1999 ; Vol. 59, No. 10. pp. 2271-2276.
@article{6c0f11fdc34549ecbf1eac0a8894d419,
title = "A novel immunological model for the study of prostate cancer",
abstract = "The Dunning R-3327 rat prostatic adenocarcinoma is a widely accepted model for in vivo experimental studies of prostate cancer. We have previously derived phenotypically distinct cell lines from a s.c. tumor resulting from the inoculation of the R-3327-5 subclone into Copenhagen rats. In this study, we report studies using a gelatin sponge model for the delivery of tumor cells and the retrieval of tumor-specific leukocytes responsive to different prostatic cell lines. S.c. preimplanted sponges were inoculated with tumor cells previously selected for differential properties of tumor formation and metastasis and examined for leukocyte content at time points of 1, 3, and 5 weeks after tumor cell inoculation. Cytospin and flow cytometric analyses revealed fewer tumor-associated leukocytes present in sponges inoculated with tumorigenic R-3327-5' and R-3327-5'B lines, with lesser sponge degradation, than in experiments with the nontumorigenic R-3327-5'A line, suggestive of a tumor cell-induced immunomodulatory mechanism. Morphological studies indicate an intermittent tumor growth pattern that gradually disappears in sponges inoculated with the nontumorigenic R-3327-5'A cells but a robust growth pattern in sponges inoculated with the tumorigenic cell lines. Cytokine analyses show the secretion of higher levels of active transforming growth factor-β by the more invasive and metastatic lines. Total transforming growth factor-β levels are higher in the epithelial, tumorigenic R-3327-5'B line. Additionally, the more tumorigenic lines secrete interleukin 10, a potent immunosuppressive molecule. In this report, we demonstrate the ability to retrieve viable leukocyte populations from a prostate tumor line bearing sponges, which offers an important model for further in vitro and in vivo manipulations and holds promise for testing adoptive immunotherapeutic strategies.",
author = "Navesh Sharma and Jun Luo and Kirschmann, {Dawn A.} and Yunxia O'Malley and Robbins, {Michael E.C.} and Akporiaye, {Emmanuel T.} and Lubaroff, {David M.} and Heidger, {Paul M.} and Hendrix, {Mary J.C.}",
year = "1999",
month = "5",
day = "15",
language = "English (US)",
volume = "59",
pages = "2271--2276",
journal = "Cancer Research",
issn = "0008-5472",
number = "10",

}

Sharma, N, Luo, J, Kirschmann, DA, O'Malley, Y, Robbins, MEC, Akporiaye, ET, Lubaroff, DM, Heidger, PM & Hendrix, MJC 1999, 'A novel immunological model for the study of prostate cancer', Cancer Research, vol. 59, no. 10, pp. 2271-2276.

A novel immunological model for the study of prostate cancer. / Sharma, Navesh; Luo, Jun; Kirschmann, Dawn A.; O'Malley, Yunxia; Robbins, Michael E.C.; Akporiaye, Emmanuel T.; Lubaroff, David M.; Heidger, Paul M.; Hendrix, Mary J.C.

In: Cancer Research, Vol. 59, No. 10, 15.05.1999, p. 2271-2276.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel immunological model for the study of prostate cancer

AU - Sharma, Navesh

AU - Luo, Jun

AU - Kirschmann, Dawn A.

AU - O'Malley, Yunxia

AU - Robbins, Michael E.C.

AU - Akporiaye, Emmanuel T.

AU - Lubaroff, David M.

AU - Heidger, Paul M.

AU - Hendrix, Mary J.C.

PY - 1999/5/15

Y1 - 1999/5/15

N2 - The Dunning R-3327 rat prostatic adenocarcinoma is a widely accepted model for in vivo experimental studies of prostate cancer. We have previously derived phenotypically distinct cell lines from a s.c. tumor resulting from the inoculation of the R-3327-5 subclone into Copenhagen rats. In this study, we report studies using a gelatin sponge model for the delivery of tumor cells and the retrieval of tumor-specific leukocytes responsive to different prostatic cell lines. S.c. preimplanted sponges were inoculated with tumor cells previously selected for differential properties of tumor formation and metastasis and examined for leukocyte content at time points of 1, 3, and 5 weeks after tumor cell inoculation. Cytospin and flow cytometric analyses revealed fewer tumor-associated leukocytes present in sponges inoculated with tumorigenic R-3327-5' and R-3327-5'B lines, with lesser sponge degradation, than in experiments with the nontumorigenic R-3327-5'A line, suggestive of a tumor cell-induced immunomodulatory mechanism. Morphological studies indicate an intermittent tumor growth pattern that gradually disappears in sponges inoculated with the nontumorigenic R-3327-5'A cells but a robust growth pattern in sponges inoculated with the tumorigenic cell lines. Cytokine analyses show the secretion of higher levels of active transforming growth factor-β by the more invasive and metastatic lines. Total transforming growth factor-β levels are higher in the epithelial, tumorigenic R-3327-5'B line. Additionally, the more tumorigenic lines secrete interleukin 10, a potent immunosuppressive molecule. In this report, we demonstrate the ability to retrieve viable leukocyte populations from a prostate tumor line bearing sponges, which offers an important model for further in vitro and in vivo manipulations and holds promise for testing adoptive immunotherapeutic strategies.

AB - The Dunning R-3327 rat prostatic adenocarcinoma is a widely accepted model for in vivo experimental studies of prostate cancer. We have previously derived phenotypically distinct cell lines from a s.c. tumor resulting from the inoculation of the R-3327-5 subclone into Copenhagen rats. In this study, we report studies using a gelatin sponge model for the delivery of tumor cells and the retrieval of tumor-specific leukocytes responsive to different prostatic cell lines. S.c. preimplanted sponges were inoculated with tumor cells previously selected for differential properties of tumor formation and metastasis and examined for leukocyte content at time points of 1, 3, and 5 weeks after tumor cell inoculation. Cytospin and flow cytometric analyses revealed fewer tumor-associated leukocytes present in sponges inoculated with tumorigenic R-3327-5' and R-3327-5'B lines, with lesser sponge degradation, than in experiments with the nontumorigenic R-3327-5'A line, suggestive of a tumor cell-induced immunomodulatory mechanism. Morphological studies indicate an intermittent tumor growth pattern that gradually disappears in sponges inoculated with the nontumorigenic R-3327-5'A cells but a robust growth pattern in sponges inoculated with the tumorigenic cell lines. Cytokine analyses show the secretion of higher levels of active transforming growth factor-β by the more invasive and metastatic lines. Total transforming growth factor-β levels are higher in the epithelial, tumorigenic R-3327-5'B line. Additionally, the more tumorigenic lines secrete interleukin 10, a potent immunosuppressive molecule. In this report, we demonstrate the ability to retrieve viable leukocyte populations from a prostate tumor line bearing sponges, which offers an important model for further in vitro and in vivo manipulations and holds promise for testing adoptive immunotherapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=0033563001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033563001&partnerID=8YFLogxK

M3 - Article

C2 - 10344727

AN - SCOPUS:0033563001

VL - 59

SP - 2271

EP - 2276

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -

Sharma N, Luo J, Kirschmann DA, O'Malley Y, Robbins MEC, Akporiaye ET et al. A novel immunological model for the study of prostate cancer. Cancer Research. 1999 May 15;59(10):2271-2276.